IQVIA
James Kyle Bryan is the Chief Medical Officer at IQVIA Biotech, a position held since February 2019, following the rebranding from Novella Clinical. With a substantial background in medical leadership, Bryan previously served as Chief Medical Officer for both Novella Clinical and VentiRx Pharmaceuticals, and held the role of Vice President of Medical Affairs at Seattle Genetics. Prior experience includes significant tenures at PPD, Inc. as Vice President of Global Product Development and at NeoRx as Director of Clinical Research. Additionally, Bryan contributed as a Trustee at Giddens School from July 2013 to June 2019. Bryan holds a Doctor of Medicine (MD) from Louisiana State University School of Medicine in New Orleans and a Bachelor of Science (BS) in Biochemistry from Louisiana State University.
This person is not in any teams
This person is not in any offices
IQVIA
156 followers
IQVIA, formerly Quintiles IMS Holdings, Inc., is an American multinational company serving the combined industries of health information technologies and clinical research. It is a provider of biopharmaceutical development and commercial outsourcing services, focused primarily on Phase I-IV clinical trials and associated laboratory and analytical services, including consulting services.